Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | IL1B | P01584 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20645748 | 0.80 | UGCG (0.51) | UGCGMEN1KMT2AKDM4EHTR2B | |
| SCHEMBL5906568 | 0.77 | BRD4 (0.47) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL14353179 | 0.75 | HDAC4 (0.44) | UGCGNPC1RAB9AKDM4EMAPT | |
| SCHEMBL14352147 | 0.75 | DHPS (0.40) | UGCGKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24637348 | 0.75 | BRD4 (0.36) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL9934256 | 0.74 | IDH1 (0.48) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL19934031 | 0.74 | TNF (0.50) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL15784143 | 0.73 | TNF (0.44) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL7952458 | 0.73 | IDH1 (0.46) | BRD4TNFIL1BIKZF1DDB1 | |
| SCHEMBL1949749 | 0.73 | BRD4 (0.44) | BRD4TNFIL1BIKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203585-B2 | Crystalline forms of lenalidomide | BIOCON LIMITED (IN) | 2021-12-21 | — | — | US | disclosed |
| US-20200347027-A1 | CRYSTALLINE FORMS OF LENALIDOMIDE | BIOCON LIMITED (IN) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347027-A1 | CRYSTALLINE FORMS OF LENALIDOMIDE | CRBN, SALL4, RDX | BRD4 187/4885TNF 687/4885IL1B 876/4885 |
| US-11203585-B2 | Crystalline forms of lenalidomide | CRBN, SALL4, RDX | BRD4 187/4885TNF 687/4885IL1B 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.